Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis
- PMID: 33443670
- DOI: 10.1007/s10072-020-05011-2
Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis
Abstract
Multidisciplinary care (MDC) has been the most recommended approach for symptom management in amyotrophic lateral sclerosis (ALS) but there is conflicting evidence about its effectiveness on survival and quality of life (QoL) of ALS patients. We conducted a systematic review to determine the effects of multidisciplinary care compared to general neurological care in survival and quality of life of ALS patients. A comprehensive literature search using Scopus, MEDLINE-PubMed, Cochrane, Web of Science, PEDro, and Science Direct was undertaken. Studies related to multidisciplinary care or general neurological care in ALS patients that assessed survival and quality of life and were published in the period up to and including January 2020 were included. A total of 1192 studies were initially identified, but only 6 were included. All studies that investigated survival showed and advantage of MDC over NC, and this benefit was even greater for bulbar onset patients. A meta-analysis was performed and showed a mean difference of 141.67 (CI 95%, 61.48 to 221.86), indicating that patients who received MDC had longer survival than those who underwent NC (p = 0.0005). Concerning QoL, only one study found better mental health scores related to QoL for patients under MDC. Multidisciplinary care is more effective than general neurology care at improving survival of patients with ALS, but only improves mental health outcomes related to quality of life of these patients.
Keywords: Amyotrophic lateral sclerosis; Meta-analysis; Multidisciplinary care; Quality of life; Survival; Systematic review.
References
-
- Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3:1–19. https://doi.org/10.1038/nrdp.2017.71
-
- Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J (2020) The clinical trial landscape in amyotrophic lateral sclerosis—past, present, and future. Med Res Rev 40:1352–1384 - DOI
-
- Logroscino G, Piccininni M (2019) Neuroepidemiology of aging-review amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference keywords amyotrophic lateral sclerosis Population-based study · cohort · registries · Global Burden of Disease · C9ORF72 · Incidence · Ancestry · Ethnicity · Geographic gradient. https://doi.org/10.1159/000493386
-
- Longinetti E, Fang F (2019) Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr Opin Neurol 32:771–776. https://doi.org/10.1097/WCO.0000000000000730
-
- Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, Hübers A, Schuster J, Weishaupt JH, Kassubek J, Gess B, Meyer T, Weyen U, Hermann A, Winkler J, Grehl T, Hagenacker T, Lingor P, Koch JC, Sperfeld A, Petri S, Großkreutz J, Metelmann M, Wolf J, Winkler AS, Klopstock T, Boentert M, Johannesen S, Storch A, Schrank B, Zeller D, Liu XL, Tang L, Fan DS, Ludolph AC (2019) Prognostic factors in ALS: a comparison between Germany and China. J Neurol 266:1516–1525. https://doi.org/10.1007/s00415-019-09290-4 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
